Neuburgh Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

Neuburgh Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$15K	Hold	2,048	–	–	﹤0.01%	897
2019 Q2	$19K	Hold	2,048	–	–	﹤0.01%	891
2019 Q1	$11K	Sell	2,048 -400	-16%	-$2.28K	﹤0.01%	899
2018 Q4	$11K	Buy	+2,448	New	+$13.4K	﹤0.01%	881
2018 Q3	–	Sell	-27,232	Closed	-$191K	–	903
2018 Q2	$191K	Buy	27,232 +1,360	+5%	+$13.3K	0.01%	658
2018 Q1	$368K	Hold	25,872	–	–	0.01%	489
2017 Q4	$227K	Sell	25,872 -2,864	-10%	-$28.3K	0.01%	623
2017 Q3	$336K	Buy	28,736 +1,808	+7%	+$22.2K	0.01%	479
2017 Q2	$376K	Buy	26,928 +10,688	+66%	+$122K	0.01%	441
2017 Q1	$223K	Hold	16,240	–	–	0.01%	477
2016 Q4	$116K	Buy	+16,240	New	+$178K	0.01%	564

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuburgh Advisers's SNDX Position: Q3 2019 in Review

Neuburgh Advisers held its Syndax Pharmaceuticals (SNDX) position steady in Q3 2019 at 2,048 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Neuburgh Advisers first reported a position in SNDX in Q4 2016 and has held it in 11 quarters since. The position peaked at $376K in Q2 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q3 2019.

Neuburgh Advisers held 2,048 shares of Syndax Pharmaceuticals worth $15K as of Q3 2019.
Neuburgh Advisers left its Syndax Pharmaceuticals share count unchanged in Q3 2019.
Syndax Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #897 holding.
Neuburgh Advisers first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 11 quarters since.
Neuburgh Advisers's Syndax Pharmaceuticals position peaked at $376K in Q2 2017.
72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.